Navigation Links
Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
Date:10/23/2007

amo BioSciences.

After achieving record sales levels in each of the last two quarters, SAFC is expected to once again set a new record for sales during the final quarter of 2007, just as it did in the final quarter of 2006. SAFC expects organic growth exceeding 7% for both the fourth quarter and the full year. As noted above, the acquisition of Epichem Group, an innovator in developing and supplying high performance semiconductor materials, is expected to add two percentage points to total Company organic sales growth for full year 2007. The Q2 2007 addition of Molecular Medicine Biosciences, which has been largely integrated into the SAFC Pharma business, will not be separately reported.

Ongoing efforts to identify and pursue other desirable acquisition candidates may further enhance growth in 2007 and 2008 as we continue to expect roughly 3% in overall additional annual revenue growth through the acquisition of strategically important products, services, platform technologies, businesses and facilities. If exchange rates remain at September 30, 2007 levels, currency would contribute in excess of four percentage points to overall reported sales growth for 2007.

Based on results for the first nine months of 2007, the sales expectations described above, currency rates remaining at September 30, 2007 levels, the expected pretax margin and tax rate described below, and other expectations for our business, we have increased our previously reported diluted earnings per share forecast by $.05 to a new range of $2.25 to $2.35, a 10% to 15% increase over 2006's $2.05. This newest upward revision is largely the result of our expectations for modest improvements in pretax margins and currency contributions and a more favorable full year tax rate from our prior forecast. Pretax income margins for the full year should be largely in line with the 21.5% achieved in the first nine months of 2007, improving on our earlier forecast to match the 21.1% achieved in 20
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Jellyfish partners for sales tracking technology
2. Doyle wants sales tax applied to digital downloads
3. Mortgagebot builds online sales even as housing declines
4. Third Wave reports another loss, stronger sales
5. Johnson Controls reports record quarterly sales
6. Can sales outsourcing grow Wisconsin biotechs?
7. Sonic Foundry reports quarterly loss, higher Mediasite sales
8. My-oh, its BIO! Where sales hype and science collide
9. Third Wave shuffles finance, sales management
10. Johnson Controls sales up, profits down
11. Turning ads into sales: Context is king
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3